Cardior eyes heart failure cure with miRNA inhibitor

Cardior unveiled data on Friday that demonstrates its first clinical candidate goes beyond treating the cardiovascular symptoms of heart failure to reversing established disease in animal models.

Cardior Pharmaceuticals GmbH, which spun out of Hannover Medical School in 2016, is

Read the full 392 word article

How to gain access

Continue reading with a
two-week free trial.